Cancer Family
Malignant Digestive System Neoplasm
CI-CAN-00000229Explore in graph →
4,262 active trials43 approved drugs556 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000229Explore in graph →
Clinical trials
19,101 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (2,000)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01095523 | Prospective Randomized Trial Evaluating Mandatory Second Look Surgery With HIPEC and CRS vs. Standard of Care in Subjects at High Risk of Developing Colorectal Peritoneal Metastases | withdrawn | Phase 2 | 0 | National Cancer Institute (NCI)NIH | 1 | Jul 2, 2017 | clinicaltrials |
| NCT01176500 | A Pilot, Open-label Study of 18F-Fluciclatide PET/CT Imaging in the Evaluation of Anti-angiogenic Therapy in Solid Tumors | withdrawn | Phase 1 / Phase 2 | 0 | National Cancer Institute (NCI)NIH | 1 | Jul 2, 2017 |
| clinicaltrials |
| NCT00039078 | Radiolabeled Glass Beads (TheraSphere®) in Treating Patients With Primary Liver Cancer That Cannot Be Removed by Surgery | withdrawn | Phase 2 | 0 | Allan TsungOTHER | 1 | Jun 26, 2017 | clinicaltrials |
| NCT00408772 | Oxaliplatin, Capecitabine, and Bevacizumab Followed By Surgery and/or Radiofrequency Ablation in Patients With Colorectal Cancer | withdrawn | Phase 2 | 0 | University of California, DavisOTHER | 1 | Jun 9, 2017 | clinicaltrials |
| NCT01646554 | Efficacy of FOLFOX Versus FOLFOX Plus Aflibercept in K-ras Mutant Patients With Resectable Liver Metastases(BOS3) | withdrawn | Phase 2 / Phase 3 | 0 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 0 | May 9, 2017 | clinicaltrials |
| NCT02856867 | Nintedanib Plus mFOLFOX6 for Previously Untreated Metastatic Esophagogastric Adenocarcinoma (MEGAN)(MEGAN) | withdrawn | Phase 2 | 0 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 0 | May 9, 2017 | clinicaltrials |
| NCT02227914 | Phase 1b/2 Study of Oprozomib in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma | withdrawn | Phase 1 / Phase 2 | 0 | AmgenINDUSTRY | 1 | May 2, 2017 | clinicaltrials |
| NCT02997956 | Study of Tocilizumab in Patients With Hepatocellular Carcinoma (HCC) Undergoing Transarterial Chemoembolization (TACE) | withdrawn | Phase 1 / Phase 2 | 0 | University of Michigan Rogel Cancer CenterOTHER | 1 | Apr 25, 2017 | clinicaltrials |
| NCT02413853 | Combination Chemotherapy and Bevacizumab With or Without PRI-724 in Treating Patients With Newly Diagnosed Metastatic Colorectal Cancer(PRIMIER) | withdrawn | Phase 2 | 0 | University of Southern CaliforniaOTHER | 1 | Apr 17, 2017 | clinicaltrials |
| NCT01270438 | Combination Chemotherapy and Bevacizumab With or Without RO4929097 in Treating Patients With Metastatic Colorectal Cancer | withdrawn | Phase 2 | 0 | National Cancer Institute (NCI)NIH | 1 | Apr 4, 2017 | clinicaltrials |
| NCT02261844 | Resveratrol and Human Hepatocyte Function in Cancer | withdrawn | Phase 1 / Phase 2 | 0 | University of LouisvilleOTHER | 1 | Mar 30, 2017 | clinicaltrials |
| NCT02857608 | A Prospective, Open-Label, Multi-center Comparison of Lymphoseek Identified Lymph Nodes and Clinically Identified Lymph Nodes of Subjects With Known Cancer of the Anus | withdrawn | Phase 2 | 0 | Cardinal Health 414, LLCINDUSTRY | 0 | Mar 15, 2017 | clinicaltrials |
| NCT02274012 | Trial of Afatinib in Combination With Weekly Paclitaxel in the Second Line Treatment | withdrawn | Phase 2 | 0 | Columbia UniversityOTHER | 0 | Mar 14, 2017 | clinicaltrials |
| NCT01895790 | Endoscopic Pancreatic Duct Stenting for Relief of Obstructive Pain in Patients With Pancreatic Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Johns Hopkins UniversityOTHER | 1 | Mar 6, 2017 | clinicaltrials |
| NCT02965417 | Sym004 in Metastatic Colorectal Cancer and ECD-EGFR Patients | withdrawn | Phase 2 | 0 | Symphogen A/SINDUSTRY | 0 | Feb 1, 2017 | clinicaltrials |
| NCT02046538 | Phase II Study of Zaltrap and Chemotherapy for Advanced Resectable Colorectal Cancer | withdrawn | Phase 2 | 0 | Weill Medical College of Cornell UniversityOTHER | 1 | Jan 25, 2017 | clinicaltrials |
| NCT02586610 | Trial of Chemoradiation and Pembrolizumab in Patients With Rectal Cancer | withdrawn | Phase 2 | 0 | Osama Rahma, MDOTHER | 0 | Jan 20, 2017 | clinicaltrials |
| NCT02785068 | Evaluation of MM-151 + Nal-IRI + 5-FU + Leucovorin in RAS/RAF Wild-type Metastatic Colorectal Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Merrimack PharmaceuticalsINDUSTRY | 0 | Jan 11, 2017 | clinicaltrials |
| NCT01522677 | A Study of Neoadjuvant Photodynamic Immunomodulation for Colon Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Edward NelsonOTHER | 1 | Dec 1, 2016 | clinicaltrials |
| NCT01335074 | Temsirolimus + Sorafenib in Advanced Hepatocellular Carcinoma (HCC) | withdrawn | Phase 1 / Phase 2 | 0 | Philipps University MarburgOTHER | 1 | Nov 15, 2016 | clinicaltrials |
| NCT02287727 | Regorafenib in Reducing Recurrence in Patients With Non-metastatic Rectal Cancer Who Have Completed Curative-Intent Treatment | withdrawn | Phase 2 | 0 | Roswell Park Cancer InstituteOTHER | 1 | Oct 12, 2016 | clinicaltrials |
| NCT01964235 | Study of Efficacy and Safety INC280 in Patients With Advanced Hepatocellular Carcinoma | withdrawn | Phase 2 | 0 | Novartis PharmaceuticalsINDUSTRY | 7 | Sep 1, 2016 | clinicaltrials |
| NCT02281279 | Rituximab, Romidepsin, and Lenalidomide in Treating Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma | withdrawn | Phase 1 / Phase 2 | 0 | Mayo ClinicOTHER | 0 | Aug 11, 2016 | clinicaltrials |
| NCT01652014 | Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Hematologic Malignancies | withdrawn | Phase 2 | 0 | University of Medicine and Dentistry of New JerseyOTHER | 1 | Jul 14, 2016 | clinicaltrials |
| NCT00571740 | Cetuximab and Bevacizumab as First-Line Therapy Followed By Combination Chemotherapy and Bevacizumab With or Without Cetuximab as Second-Line Therapy in Treating Patients With Stage IV Colorectal Cancer | withdrawn | Phase 2 | 0 | Alliance for Clinical Trials in OncologyOTHER | 0 | Jul 6, 2016 | clinicaltrials |
| NCT01473303 | Combination Chemotherapy With or Without Ganitumab in Treating Patients With Previously Untreated Metastatic Pancreatic Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Alliance for Clinical Trials in OncologyOTHER | 0 | Jun 28, 2016 | clinicaltrials |
| NCT00800969 | Prospective Evaluation of the Preoperative Lymph Node Staging in Patients With Cancer of the Esophagogastric Junction and Stomach | withdrawn | Phase 2 | 0 | University of ZurichOTHER | 1 | Jun 23, 2016 | clinicaltrials |
| NCT02575508 | Pan FGFR Kinase Inhibitor BGJ398 and Combination Chemotherapy in Treating Patients With Untreated Metastatic Pancreatic Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Roswell Park Cancer InstituteOTHER | 1 | May 20, 2016 | clinicaltrials |
| NCT01953406 | The Efficacy of 5-fluorouracil/Mitomycin for the Patients With Pulmonary Metastasis of Hepatocellular Carcinoma | withdrawn | Phase 2 | 0 | Seoul National University HospitalOTHER | 1 | Apr 27, 2016 | clinicaltrials |
| NCT01157039 | A Trial of Glutamine to Prevent Oxaliplatin Neurotoxicity and a Pharmacokinetic Analysis of Oxaliplatin | withdrawn | Phase 2 | 0 | AHS Cancer Control AlbertaOTHER | 0 | Feb 24, 2016 | clinicaltrials |
| NCT00227773 | Vatalanib and Octreotide in Treating Patients With Progressive Neuroendocrine Tumors | withdrawn | Phase 2 | 0 | Eastern Cooperative Oncology GroupNETWORK | 0 | Oct 8, 2015 | clinicaltrials |
| NCT01598584 | Mirtazapine Plus Gemcitabine Versus Gemcitabine in Metastasis Pancreatic Cancer | withdrawn | Phase 2 / Phase 3 | 0 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Sep 28, 2015 | clinicaltrials |
| NCT01501604 | BKM120 in Cancers With PIK3CA Activating Mutations | withdrawn | Phase 2 | 0 | Massachusetts General HospitalOTHER | 0 | Sep 17, 2015 | clinicaltrials |
| NCT00244348 | Hepatic Artery Infusion With Oxaliplatin | withdrawn | Phase 1 / Phase 2 | 0 | Medical College of WisconsinOTHER | 1 | Aug 27, 2015 | clinicaltrials |
| NCT01775280 | Response of Hepatic Tumors to Radioembolization(RESRAD) | withdrawn | Phase 2 | 0 | University of ZurichOTHER | 1 | Jun 9, 2015 | clinicaltrials |
| NCT01301495 | Prospective Evaluation of a New Covered Metal Stent for Malignant Lesions of the Esophagus | withdrawn | Phase 2 | 0 | Weill Medical College of Cornell UniversityOTHER | 1 | Jun 3, 2015 | clinicaltrials |
| NCT00735241 | FOLFOX6 Plus Sir-Spheres Microspheres Plus Avastin in Patients With Nonresectable Liver Metastases From Colorectal Carcinoma(FAST) | withdrawn | Phase 2 / Phase 3 | 0 | Sirtex MedicalINDUSTRY | 1 | May 22, 2015 | clinicaltrials |
| NCT02235324 | Ziv-Aflibercept Followed by Ziv-Aflibercept, Fluorouracil, and Leucovorin Calcium in Treating Patients With Stage IV Colorectal Cancer | withdrawn | Phase 2 | 0 | University of Southern CaliforniaOTHER | 1 | May 6, 2015 | clinicaltrials |
| NCT00253526 | Gemcitabine Hydrochloride With or Without Bevacizumab in Treating Patients Who Are Undergoing Surgery for Pancreatic Cancer | withdrawn | Phase 2 | 0 | National Cancer Institute (NCI)NIH | 0 | Apr 28, 2015 | clinicaltrials |
| NCT02310971 | Cvac as Maintenance Treatment Patients With Resected Stage I or Stage II Adenocarcinoma (Cancer) of the Pancreas | withdrawn | Phase 2 | 0 | Prima BioMed LtdINDUSTRY | 0 | Apr 3, 2015 | clinicaltrials |
| NCT01130701 | A Pilot Study to Evaluate the Efficacy and Safety of Neoadjuvant Chemoradiotherapy With Capecitabine, . . .(PMABIIS) | withdrawn | Phase 2 | 0 | University of Massachusetts, WorcesterOTHER | 1 | Mar 17, 2015 | clinicaltrials |
| NCT02033538 | Neoadjuvant Chemotherapy of Nanoparticle Albumin-bound Paclitaxel in Squamous Cell Carcinoma of Esophagus | withdrawn | Phase 2 | 0 | Zhejiang UniversityOTHER | 1 | Mar 5, 2015 | clinicaltrials |
| NCT02034968 | Nimotuzumab Plus Nab-paclitaxel and Cisplatin in Treating Patients With Advanced Esophageal Carcinoma | withdrawn | Phase 2 | 0 | Zhejiang UniversityOTHER | 1 | Mar 5, 2015 | clinicaltrials |
| NCT02041819 | Neoadjuvant Chemotherapy of Nimotuzumab Plus Nab-Paclitaxel in Squamous Cell Carcinoma of Esophagus | withdrawn | Phase 2 | 0 | Zhejiang UniversityOTHER | 1 | Mar 5, 2015 | clinicaltrials |
| NCT00575640 | Hydralazine as a Demethylating Agent in Rectal Cancer | withdrawn | Phase 1 / Phase 2 | 0 | University of ArkansasOTHER | 0 | Mar 4, 2015 | clinicaltrials |
| NCT02011594 | Phase II Study of Maintenance Treatment of Nimotuzumab for Advanced Esophageal Carcinoma | withdrawn | Phase 2 | 0 | Zhejiang UniversityOTHER | 1 | Feb 12, 2015 | clinicaltrials |
| NCT01659424 | Phase II Trial of Preoperative High-dose-rate Endorectal Brachytherapy and FOLFOX Chemotherapy for Rectal Cancer(HDRBT) | withdrawn | Phase 2 | 0 | Beth Israel Medical CenterOTHER | 1 | Dec 18, 2014 | clinicaltrials |
| NCT01889680 | Safety and Effectiveness Study of Chemotherapy and Ziv-aflibercept to Treat Metastatic Colorectal Cancer | withdrawn | Phase 2 | 0 | NSABP Foundation IncNETWORK | 0 | Dec 2, 2014 | clinicaltrials |
| NCT02070419 | TACE With or Without Radiation Therapy in Treating Patients With Stage A-C Liver Cancer | withdrawn | Phase 2 | 0 | Case Comprehensive Cancer CenterOTHER | 0 | Dec 2, 2014 | clinicaltrials |
| NCT00808145 | Study of Sorafenib, Gemcitabine, and Cisplatin in Advanced Hepatocellular Carcinoma (HCC) | withdrawn | Phase 2 | 0 | Lahey ClinicOTHER | 1 | Oct 22, 2014 | clinicaltrials |
Data updated 23 days agoSource updated Jul 2, 2017source: clinicaltrials